Abstract:There is currently no specific therapeutics for the HIV-1-related central nervous system (CNS) complications. Here we report that three newly designed CNS-targeting HIV-1 protease inhibitors (PIs), GRL-083-13, GRL-084-13, and GRL-087-13, which contain a P1-3,5-bis-fluorophenyl or P1-para-monofluorophenyl ring, and P2-bis-tetrahydrofuran (bis-THF) or P2-tetrahydropyrano-tetrahydrofuran (Tp-THF), with a sulfonamide isostere, are highly active against wild-type HIV-1 strains and primary clinical isolates (50% effective concentration [EC50], 0.0002 to ∼0.003 μM), with minimal cytotoxicity. These CNS-targeting PIs efficiently suppressed the replication of HIV-1 variants (EC50, 0.002 to ∼0.047 μM) that had been selected to propagate at high concentrations of conventional HIV-1 PIs. Such CNS-targeting PIs maintained their antiviral activity against HIV-2ROD as well as multidrug-resistant clinical HIV-1 variants isolated from AIDS patients who no longer responded to existing antiviral regimens after long-term therapy. Long-term drug selection experiments revealed that the emergence of resistant-HIV-1 against these CNS-targeting PIs was substantially delayed. In addition, the CNS-targeting PIs showed the most favorable CNS penetration properties among the tested compounds, including various FDA-approved anti-HIV-1 drugs, as assessed with the in vitro blood-brain barrier reconstruction system. Crystallographic analysis demonstrated that the bicyclic rings at the P2 moiety of the CNS-targeting PIs form strong hydrogen-bond interactions with HIV-1 protease (PR) active site. Moreover, both the P1-3,5-bis-fluorophenyl and P1-para-monofluorophenyl rings sustain greater van der Waals contacts with PR than in the case of darunavir (DRV). The data suggest that the present CNS-targeting PIs have desirable features for treating patients infected with wild-type and/or multidrug-resistant HIV-1 strains and might serve as promising preventive and/or therapeutic candidates for HIV-1-associated neurocognitive disorders (HAND) and other CNS complications.

Strategies to target the central nervous system HIV reservoir

Research progress on HIV latency-reversing agents and its mechanism

Reservoir of Human Immunodeficiency Virus in the Brain: New Insights into the Role of T Cells

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs

Harnessing immune cells to eliminate HIV reservoirs

Targeting HIV persistence in the tissue

Humanized mice for studying HIV latency and potentially its eradication

Mechanisms of HIV-1 Neurotropism

Delivering CRISPR to the HIV-1 reservoirs

Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications

Animal Models for Studies of HIV-1 Brain Reservoirs

Strategies for HIV-1 suppression through key genes and cell therapy

Mechanisms of HIV-Mediated Blood-Brain Barrier Compromise and Leukocyte Transmigration under the Current Antiretroviral Era.

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

Targeting Viral Transcription for HIV Cure Strategies

Translational eradication approaches

Functional compartmentalization of antibodies in the central nervous system during chronic HIV infection

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?